NightBalance B.V.

NightBalance B. V. focuses on developing advanced sleep and respiratory care solutions, particularly optimizing Continuous Positive Airway Pressure (CPAP) devices to aid individuals suffering from sleep apnea, enhancing patient adherence and comfort. Founded in 2009 and headquartered in The Hague, Netherlands, NightBalance B.

V. specialized in sleep apnea management solutions. In May 2018, NightBalance became a subsidiary of Philips International B. V.

through an acquisition, enhancing its operational capabilities. The company has completed a total of 4 deals, with its most recent funding round being a Series B round, which raised EUR 12. 50 mn from investors including Gilde Healthcare, Health Innovations, Inkef, Thuja Capital, and Van Herk Group. The total amount raised by NightBalance stands at EUR 12.

50 mn. NightBalance provided innovative sleep and respiratory care products, particularly Continuous Positive Airway Pressure (CPAP) and Bi-Level Positive Airway Pressure (BiPAP) devices designed to manage sleep apnea. These devices ensured airflow to keep airways open during sleep. However, the flagship product, NightBalance, was discontinued in September 2023.

Existing devices will continue to be supported by Philips Respironics until May 2027. The primary clientele included healthcare providers, hospitals, and individual patients mainly in the United States and Canada. In the most recent financial year, 2015, NightBalance reported a revenue of EUR 578,996 and an EBITDA of EUR -1,082,686. The revenue model involved direct sales and partnerships with healthcare institutions, primarily through B2B relationships, with a focus on CPAP and BiPAP device bulk purchases.

Ongoing support agreements for these devices contributed to a recurring revenue stream, reflecting a commitment to customer engagement and device longevity. Following the acquisition by Philips in May 2018, NightBalance aims to leverage the resources and technology of its parent company to enhance its product offerings and market reach. While specific new products have not been publicly detailed, the company is expected to explore opportunities in new markets, particularly within the European Union and Asia, by 2025. Recent funding will be utilized to support these expansion efforts and enhance product development initiatives.